Govardhan Dhoot Is The Chairman & MD of Mangalam Drugs & Organics And They Just Sold 47% Of Their Shares
Sandur Manganese & Iron Ores Ltd leads gainers in `B` group
Net profit of Mangalam Drugs and Organics declined 37.48% to Rs 4.02 crore in the quarter ended December 2021 as against Rs 6.43 crore during the previous quarter ended December 2020. Sales rose 5.81% to Rs 93.84 crore in the quarter ended December 2021 as against Rs 88.69 crore during the previous quarter ended December 2020. ParticularsQuarter EndedDec. 2021Dec. 2020% Var.Sales93.8488.69 6 OPM %6.6814.21 -PBDT11.6211.52 1 PBT8.959.19 -3 NP4.026.43 -37
Mangalam Drugs And Organics Limited has reported Standalone financial results for the period ended December 31, 2021.
Mangalam Organics jumped 11.68% to Rs 888 after the company reported 55.7% rise in consolidated net profit to Rs 22.31 crore on a 66.6% increase in net sales to Rs 143.05 crore in Q2 FY22 over Q2 FY21.
Emzor announces API Manufacturing Technology Transfer and Licensing Agreement with India’s Mangalam Drugs & Organics Limited, to locally manufacture in Nigeria and distribute Active Pharmaceutical Ingredients (APIs) for the treatment and prevention of malaria.
The company has received an advance payment of USD 500,000 towards the agreed fixed consideration.nnAugust 12, 2021 9:36 IST | India Infoline News Service
The rating upgrade reflects MD&OL’s robust revenue growth, healthy margins and improved credit metrics in FY21
Net profit of Mangalam Organics declined 49.06% to Rs 15.12 crore in the quarter ended December 2021 as against Rs 29.68 crore during the previous quarter ended December 2020. Sales rose 9.25% to Rs 117.57 crore in the quarter ended December 2021 as against Rs 107.62 crore during the previous quarter ended December 2020. ParticularsQuarter EndedDec. 2021Dec. 2020% Var.Sales117.57107.62 9 OPM %20.9040.85 -PBDT23.9244.02 -46 PBT20.0440.25 -50 NP15.1229.68 -49